Evaluation of novel compounds as anti-bacterial or anti-virulence agents
Article (Published version)
Metadata
Show full item recordAbstract
Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-k...ill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.
Keywords:
anti-bacterial assays / anti-virulence assays / antimicrobial resistance / molecular docking / novel compounds / QSAR / virulence factorsSource:
Frontiers in Cellular and Infection Microbiology, 2024, 14Publisher:
- Frontiers
Funding / projects:
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200161 (University of Belgrade, Faculty of Pharmacy) (RS-MESTD-inst-2020-200161)
URI
https://www.frontiersin.org/articles/10.3389/fcimb.2024.1370062https://imagine.imgge.bg.ac.rs/handle/123456789/2333
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Filipić, Brankica AU - Ušjak, Dušan AU - Rambaher, Martina Hrast AU - Oljacic, Slavica AU - Milenković, Marina PY - 2024 UR - https://www.frontiersin.org/articles/10.3389/fcimb.2024.1370062 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2333 AB - Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials. PB - Frontiers T2 - Frontiers in Cellular and Infection Microbiology T1 - Evaluation of novel compounds as anti-bacterial or anti-virulence agents VL - 14 DO - 10.3389/fcimb.2024.1370062 ER -
@article{ author = "Filipić, Brankica and Ušjak, Dušan and Rambaher, Martina Hrast and Oljacic, Slavica and Milenković, Marina", year = "2024", abstract = "Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.", publisher = "Frontiers", journal = "Frontiers in Cellular and Infection Microbiology", title = "Evaluation of novel compounds as anti-bacterial or anti-virulence agents", volume = "14", doi = "10.3389/fcimb.2024.1370062" }
Filipić, B., Ušjak, D., Rambaher, M. H., Oljacic, S.,& Milenković, M.. (2024). Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology Frontiers., 14. https://doi.org/10.3389/fcimb.2024.1370062
Filipić B, Ušjak D, Rambaher MH, Oljacic S, Milenković M. Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1370062 .
Filipić, Brankica, Ušjak, Dušan, Rambaher, Martina Hrast, Oljacic, Slavica, Milenković, Marina, "Evaluation of novel compounds as anti-bacterial or anti-virulence agents" in Frontiers in Cellular and Infection Microbiology, 14 (2024), https://doi.org/10.3389/fcimb.2024.1370062 . .